MedTrace Logo

Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib

NCT03386825 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2018-05-15

No results posted yet for this study

Summary

The aim of this local NIS(Non-Interventional Study) is to determine the proportion of Belgian patients with a duration of treatment(DoT) to Stivarga of 4 months or more in relation to the total population of Belgian metastatic colorectal cancer(mCRC) patients who were treated with Stivarga between the 1st of July 2015 and 31 July 2017. In addition, this study aims to describe the clinical characteristics of Belgian patients with a short- or long-term DoT to Stivarga.

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

Antineoplastic agents, protein kinase inhibitor (L01XE21)

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2018-05-01
Completion
2018-05-01

Countries

  • Belgium

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03386825 on ClinicalTrials.gov